Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe 10:21:53 2024-05-21 am EDT 5-day change 1st Jan Change
235.6 CHF -0.61% Intraday chart for Roche Holding AG +5.03% -3.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Roche: Breakthrough designation for inavolisib in breast cancer CF
Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation DJ
Roche's Investigational Breast Cancer Treatment Granted Breakthrough Designation by US FDA MT
UK Competition Watchdog Considers Probe into Roche's Purchase of LumiraDx Business MT
U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx DJ
UK'S CMA: INVITES COMMENTS ON ROCHE / LUMIRADX DEAL FROM ANY IN… RE
Health Care Up on Rotation to Sector From Rate-Sensitive Groups -- Health Care Roundup DJ
ROCHE HOLDINGS AG : UBS sticks Neutral ZD
Deutsche Bank Upgrades Roche to Hold from Sell MT
ROCHE : Deutsche Bank no longer sells CF
Roche: share price stands out, Deutsche Bank in support CF
ROCHE HOLDINGS AG : Deutsche Bank Upgrades to Neutral ZD
Swiss Market Index Rises; Roche Shines on Promising Weight-loss Drug MT
Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... Our Logo
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 DP
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study MT
ROCHE HOLDINGS AG : Receives a Sell rating from JP Morgan ZD
News Highlights : Top Company News of the Day - Thursday at 7 AM ET DJ
ROCHE HOLDINGS AG : Jefferies remains Neutral ZD
European shares slip on auto, energy drag; Siemens drops on bleak earnings RE
Roche shares boosted by good results in obesity treatment CF
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial DJ
Roche shares gain on obesity drug results from early-stage trial RE
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Calendar
2024-05-22 - Investor Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW